Medicus Pharma Ltd. (MDCX)

Price$0.1752Cached quoteAs of 2026-09-04 16:23 UTC

AI: Fair-priced

Price checkThe equity looks cheap by market value, but obligations and financing risk keep that signal misleading.

Medicus Pharma Ltd., trading on the Nasdaq Capital Market as MDCX, is valued by the market at roughly $10.8 million using the latest quoted market capitalization. That is small beside the June balance-sheet liabilities and the cash commitments added by the September Pfizer license. For a pre-revenue biotech, price-to-earnings or sales multiples are not useful; the right comparison is market value against available cash, debt, expected cash burn, and risk-adjusted pipeline value. On that basis, the apparent cheapness is not decisive.

Big pictureClinical optionality is real, but cash durability is weak once debt, burn, and Pfizer payments are considered.

At June 30, Medicus had $15.2 million of unrestricted cash, about $10.0 million of restricted cash, and roughly $21.5 million of recorded secured notes, while six-month operating cash use reached $16.0 million. Management disclosed substantial doubt about continuing as a going concern without more financing. The September CD228V deal then required a $12.0 million upfront payment, partly offset by $2.0 million of development funding restricted to that program, plus another $15.0 million due one year later. That makes the June cash snapshot materially stale.

Business strengthSkinJect, Teverelix, and CD228V create multiple shots on goal, but none currently produces operating revenue.

The business has three meaningful clinical assets or platforms and recent regulatory progress, which reduces reliance on a single experiment. SkinJect produced encouraging Phase 2 clearance data; Teverelix has several regulator-reviewed development paths; and CD228V adds an oncology program with Pfizer involvement. Still, these are development-stage assets, not durable earnings streams. Biotech demand is not conventionally cyclical, but financing conditions are: weak risk appetite can make capital expensive exactly when trials require funding. Clinical failures, delays, or weak partnering terms could therefore hit both value and liquidity.

What could change the storyBetter trial evidence or partnerships could unlock upside; another financing wave, delisting pressure, or setbacks could overwhelm it.

Bull case: CD228V produces convincing proof-of-concept, SkinJect or Teverelix secures a funded partnership, and Pfizer later shares pivotal-development costs, allowing Medicus to meet obligations without heavy equity issuance. Bear case: studies disappoint or slip, the company must refinance secured debt and the future Pfizer payment while cash burn stays high, and Nasdaq compliance pressures force a restructuring or reverse split. Share dilution already matters: the ATM program issued tens of millions of shares in 2026. Because both outcomes are plausible, I view the equity as fair-priced rather than clearly cheap.

AI: News

Precision oncology pivotMedicus made CD228V its main strategic priority and shifted SkinJect and Teverelix toward partnership-led development.

On September 8, Medicus said it is repositioning around precision oncology, with CD228V as the principal internal development priority. Management plans to seek capital-efficient partnerships for SkinJect and Teverelix rather than fund every program fully itself. The shift could concentrate spending and reduce future burn, but it also makes partner economics and execution central to the investment case. It followed the newly signed Pfizer agreement for CD228V.

Pfizer CD228V licenseA Pfizer license adds an early-stage oncology asset, while creating large fixed and contingent payment obligations.

The September 2 agreement gives Medicus worldwide development and commercialization rights to CD228V, an early clinical-stage antibody-drug conjugate, while Pfizer retains underlying patents and economic participation. Medicus paid $12.0 million upfront, receives $2.0 million earmarked for development, and owes $15.0 million on the first anniversary. Pfizer may also receive more than $1.0 billion of potential milestones and low double-digit royalties if the program succeeds. The deal materially changes both pipeline upside and financing needs.

Second-quarter loss widensResearch spending accelerated and cash rose through financing, but the company still flagged going-concern uncertainty.

For the June quarter, Medicus reported a $11.7 million net loss and $11.5 million of operating expenses as research and administrative spending increased. Unrestricted cash was $15.2 million, with additional restricted cash tied to financing arrangements. The company had raised substantial equity and debt capital during the first half, yet its filing still said substantial doubt existed about continuing as a going concern without additional financing. That tension between clinical progress and funding dependence remains central.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$0	$0	$0	$0
Research & development	$8.7M	$0	$193,578	$646,384
Operating expenses	$34.4M	$11.2M	$4.7M	$978,416
Operating income	−$34.4M	−$11.2M	−$4.7M	−$978,416
EBITDA	−$34.4M	−$11.2M	−$2.7M	−$1.2M
Net income	−$47.3M	−$11.2M	−$5.3M	−$1.7M
Basic EPSper basic share	-$2.74	-$1.16	-$1.53	-$0.88
Diluted EPSper diluted share	-$2.74	-$1.16	-$1.53	-$0.88

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders

Top 20 reported holders of MDCX
Holder	Shares held
VELOCITY FUND PARTNERS, LP / Melani Kenneth R.	3.32M
215 Capital TOGO PHL Fund I, LP / Togo PHL Management LLC / Raju Ajay	2M
Interchange Capital Partners, LLC	1.59M
Bokhari Raza	793.17K
JANE STREET GROUP, LLC	333.67K
XTX Topco Ltd	243.36K
Sterling Investment Advisors, Ltd.	100K
Brennan Edward J.	86.5K
COMMONWEALTH EQUITY SERVICES, LLC	52.64K
May Hill Capital, LLC	50.62K
MAHAFFY PATRICK J	35.44K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	31.46K
STIFEL FINANCIAL CORP	30K
JPMORGAN CHASE & CO	25.62K
Wilmington Savings Fund Society, FSB	25.62K
Lavelle Frank W	25.62K
CITADEL ADVISORS LLC	25.1K
Smithfield Trust Co	24.61K
Stratos Wealth Partners, LTD.	20.95K
Bonner Carolyn F.	18.91K

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 3/A ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)1$579.0K disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
May 20, 2025Form 4	Melani Kenneth R. +1TenPercentOwner	SellMedicus Pharma LTD · indirect	75.0K	$7.72	$579.0K	3.25M

Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about MDCX yet. Start the conversation.

Write the first post

Medicus Pharma Ltd. (MDCX)

Financial charts

Financial statements

Owners

Insider buys & sells

Community posts

It’s quiet here.